Copenhagen, 20 August 2009 - NeuroSearch (NEUR) announces that the timetable
for the issue of 618,562 new shares to Johnson & Johnson Development
Corporation relating to a new drug discovery and drug development alliance
between NeuroSearch and Janssen Pharmaceutica NV as described in announcement
no. 34-09 has been changed.

As of today, the capital increase has been registered with the Danish Commerce
and Companies Agency ('Erhvervs- og Selskabsstyrelsen'), and the new shares are
now expected to be admitted for trading and official listing on the NASDAQ OMX
Copenhagen exchange under the ISIN code of NeuroSearch's existing shares (ISIN
code DK0010224666) on 25 August 2009.

Expected timetable for the capital increase

Date / Event:

20 August 2009
Registration of the new shares with the Commerce and Companies Agency as well
as issue and registration of the new shares with VP Securities Services.

25 August 2009
Admittance for trading and official listing of the new shares with the NASDAQ
OMX Copenhagen exchange.


Flemming Pedersen
CEO


Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103



About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Eli Lilly and Company, Janssen Pharmaceutica and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. NeuroSearch's
pipeline of drug candidates comprises seven clinical (Phase I-III) development
programmes: Pridopidine (ACR16) for Huntington's disease (Phase III),
tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in
partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease
(Phase Ib), ACR343 for schizophrenia (Phase II ready), ABT-560 for the
treatment of various CNS disorders (Phase I) in collaboration with Abbott, and
NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad
portfolio of preclinical drug candidates and holds equity interests in several
biotech companies.

fonds.35-09 - jjdc issue_new timetable - uk - final.pdf